Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026
Rhea-AI Summary
Evaxion (NASDAQ: EVAX) will release a business update and first quarter 2026 financial results on May 7, 2026, before Nasdaq opening. Management will host a conference call and webcast on the same day at 14:30 CET / 08:30 EST. Registration is required to obtain dial-in numbers and a PIN.
The webcast will open 15 minutes early and a recording will be posted on the company website shortly after the event. Contact: Mads Kronborg, Vice President, Investor Relations & Communication.
Positive
- None.
Negative
- None.
News Market Reaction – EVAX
In the May 4 session, EVAX gained 1.67%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 02 | Earnings date notice | Neutral | +0.3% | Scheduled full year 2025 results call for Mar 5, 2026. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior earnings-date scheduling news for EVAX led to a very modest price move, suggesting this type of announcement has historically been a low-volatility catalyst.
This announcement fits a period of frequent news for Evaxion. In April 2026, the company reported positive phase 2 data for EVX-01 with strong response rates and durable immunity, and highlighted the broader scalability of its AI-Immunology™ platform, both coinciding with mid‑single‑digit percentage gains. Governance items such as the April 16, 2026 AGM and an executive promotion on April 27, 2026 saw smaller reactions. Against this backdrop, today’s earnings-date notice continues the pattern of regular, structured communication, similar to the March 5, 2026 full-year results call scheduling.
Key Terms
nasdaq cm financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
COPENHAGEN, Denmark, May 4, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its first quarter 2026 financial results on Thursday May 7, 2026, before opening of the Nasdaq CM.
Evaxion’s Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions.
To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be accessed 15 minutes prior to the start of the live event.
To join the webcast, please click on this link. The webcast recording will be available on our website shortly after the event.
Contact information
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai
About Evaxion
Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.
With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development
We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.
For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website.
Forward-looking statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.
